Pharmaceutical Partners announces the launch of a U.S. clinical trial of Abraxane in the combined treatment of the most commonly used chemotherapy of paclitaxel and trastuzumab in patients with HER2-positive. – Study with ION, the largest network of oncologists are carried out in the community – for ABRAXANE administered weekly in combination with Herceptin in first-line treatment for metastatic breast cancer, American Pharmaceutical Partners, Inc. (Nasdaq: CIRCA) announced today that American BioScience, Inc. ..
administered weekly Herceptin in first-line treatment of metastatic breast cancer in combination. The study will be conducted by the International Oncology Network (ION), leading nations and the largest network of oncologists in the community and will have 20 IONdemonstrated superiority over Taxol (R) in terms of response rate, time to tumor progression and survival. The combination of Herceptin with ABRAXANE in the absence of premedication with steroids is an important addition to the arsenal used by oncologists to treat patients with breast cancer. ABRAXANE (TM) was passed February 7, 2005 by Abraxis Oncology, a division of property of the APA, after receiving FDA approval in January.
Pages:  2 3